|
|
|
| home > pmps > autumn 2003 > knowledge sharing in the clinical trials industry - annex 13 |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
Let us start with the core functions provided by BlisTech UK.
BlisTech Clinical Trial Packaging Ltd's primary function is to provide a comprehensive clinical trial packaging service, providing primary and secondary packaging in a variety of presentations. BlisTech also provide storage, distribution and have two qualified persons (QPs) available for batch release under 75/319/EEC (2001/183/EEC). We also package and provide QP release for commercial products.
In our recent interview with Joseph Saccamono (PMPS Spring 2003) we talked about the aspect of technical knowledge sharing. How has that changed the demands of the European pharmaceutical companies?
Annex 13 has been the classic case where technical knowledge sharing has been crucial. The pharma business has had to wake up to the new GMP requirements to ensure they will be able to initiate and/or continue their clinical trials in May 2004. BlisTech has been sharing information in preparation for QP certification of batches for IMPs in 2004 with new and existing clients, as and when necessary. BlisTech have also employed two QPs to ensure their clients' needs will be met and will be applying for the new IMP Licence when the application forms are released by the MHRA.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
UBC APPOINTS BEKKI BROWN PRESIDENT & CHIEF EXECUTIVE OFFICER
Effective January 1, 2023, Bekki Brown will assume the role of President & Chief Executive Officer of UBC
More info >> |
|
 |
White Papers |
 |
|
Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections
IBT Bioservices
Introduction
Staphylococcus aureus (SA) is a ubiquitous, formidable
Gram-positive pathogen associated with skin and soft tissue, as well as
lifethreatening systemic infections. SA is a leading cause of hospital- and
community-associated infections worldwide, affecting humans and animals. The
wide range of pathologies reflects the diverse abilities of this microbe to
escape the innate and adaptive immune response using virulence factors. Since
its first emergence in the 1960s methicillin-resistant SA (MRSA) has become
endemic in hospitals and healthcare settings worldwide. In the 1990s, community
associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a
major global challenge.
More info >> |
|
|
